Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 598.51% and ...

Eli Lilly (LLY) stock is trading near its all-time highs ... They've gotten the green light from the FDA for some important new drugs, like Kisunla for Alzheimer's - which is now being used clinically ...

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

Japan is the second major market where LLY's Kisunla has been approved. The drug was first approved in the United States in ...

In particular, semiconductor specialist Nvidia is viewed as the engine powering the AI vehicle right now. Demand for its most ...

Eli Lilly has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Kisunla (donanemab-azbt) ...

Eli Lilly and Co. wants a federal court to uphold a simple math equation: 41 is greater than 40. The Indianapolis-based drugmaker filed a lawsuit in federal court this month, challenging the U.S. Food ...

Roche narrows pipeline to focus more on weight-loss franchise, following setbacks in Alzheimer's and lung cancer ...

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

(RTTNews) - Eli Lilly and Company (LLY) Tuesday said its Kisunla for the treatment of adults with early symptomatic Alzheimer's disease has been approved by the Ministry of Health, Labour and Welfare ...